Pharmafile Logo

Research Partnership ranks 13th in the top 20 fastest-growing agencies in the UK

February 4, 2019 | Pharma, healthcare, market research 

The UK’s best performing market research agencies were revealed earlier this month with the publication of Research Live’s Industry Report for 2019, which includes the latest Market Research Society (MRS) League Tables. Based on 2017 financial data that was compiled and analysed in November 2018, the MRS league tables identify and rank the best-performing research agencies and businesses according to their UK-based turnover and by their year-on-year growth.

With a growth rate of 21.87%, Research Partnership has been ranked 13th in the top 20 fastest-growing individual agencies. In addition, with over £27.5 million in sales, the company ranked 25th in the top 50 consolidated businesses, which draws agencies together under ownership groups, and 27th in the top 100 individual agencies, both of which are ranked by annual turnover.

Founding Director Mark Jeffery was interviewed for the report’s ‘Perspective from the Fastest Growers’ to find out how Research Partnership is achieving growth in an uncertain climate. Mark commented, “We are delighted to see Research Partnership placed so well in the league tables again this year. Our senior level and business development teams work hard to secure new clients, and our research teams ensure that we receive repeat business by delivering the very best service. We celebrated our 20th anniversary last year and have enjoyed consistent growth every year since we started. As a result we are now the largest independent healthcare market research agency in the world, working with all the major global pharma organisations.”

In the past year Research Partnership’s has also expanded into the medical technology space, built up the company’s market access capabilities, opened three new offices across the US and Europe, and grown the workforce by 15%.

Read the full report here »

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Eyeforpharma Real World Evidence Conference Round up 2018

Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)This year has seen a turning point...

EphMRA Annual Conference 2018

Visit us on stand number 20

Connected Patients – Adopting a patient-centric approach in emerging markets

The concept of patient centricity and putting the patient at the heart of care is being widely adopted by the healthcare industry – the general consensus being that it’s going...

Combination therapies in oncology: The benefits of integrated insights

14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE

Intellus round up 2018

Earlier this month, US President Harriet Kozak and Emerging Markets Director Rachel Howard attended the inaugural Intellus Worldwide Summit in Philadelphia

Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research...

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

How integrated insights supported a biologic launch strategy across multiple indications

Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their...

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...